US29089Q1058
© Globe Newswire
12.12.2025
EBS
LISTED
NYSE
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
News Preview
GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal an...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
EBS
LISTED
NYSE
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
News Preview
GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
EBS
LISTED
NYSE
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
News Preview
GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
19.09.2025
EBS
LISTED
NYSE
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
News Preview
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) busines...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
15.09.2025
EBS
LISTED
NYSE
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
News Preview
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
EBS
LISTED
NYSE
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
News Preview
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
EBS
LISTED
NYSE
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
News Preview
GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE: EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among young adults at...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
EBS
LISTED
NYSE
Emergent BioSolutions to Participate in Upcoming Investor Conferences
News Preview
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
EBS
LISTED
NYSE
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
News Preview
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Servi...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
EBS
LISTED
NYSE
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
News Preview
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
EBS
LISTED
NYSE
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
News Preview
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Hep...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
EBS
LISTED
NYSE
Emergent BioSolutions Announces Addition to Russell 3000® Index
News Preview
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
05.06.2025
EBS
LISTED
NYSE
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
News Preview
GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria’s Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victor...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
EBS
LISTED
NYSE
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
News Preview
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
EBS
LISTED
NYSE
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
News Preview
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
EBS
LISTED
NYSE
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
News Preview
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
EBS
LISTED
NYSE
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
News Preview
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
EBS
LISTED
NYSE
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
News Preview
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd fam...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.03.2025
EBS
LISTED
NYSE
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
News Preview
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
EBS
LISTED
NYSE
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.02.2025
EBS
LISTED
NYSE
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
News Preview
GAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend and NARCAN® Nasal Spray spokesperson, Emmitt Smith, as the city welcomes an anticipated 83,000 fans for the Big Game. For the past two ye...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2025
EBS
LISTED
NYSE
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
News Preview
Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
EBS
LISTED
NYSE
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
News Preview
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the se...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2024
EBS
LISTED
NYSE
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
News Preview
GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
EBS
LISTED
NYSE
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
News Preview
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sustain the U.S. government’s national preparedness posture against human smallpox. TEMBEXA® is indicated for t...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
EBS
LISTED
NYSE
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
News Preview
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 $185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.09.2024
EBS
LISTED
NYSE
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
News Preview
GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolution...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
EBS
LISTED
NYSE
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
News Preview
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
EBS
LISTED
NYSE
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
News Preview
GAITHERSBURG, Md., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is kicking off the second year of the Ready to Rescue initiative, which will include new college football tailgate stops, in-stadium activities, Greek Life events and student wellness clinics. As part of these expanded efforts, pro foot...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
EBS
LISTED
NYSE
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
News Preview
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpo...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2024
EBS
LISTED
NYSE
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
News Preview
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2024
EBS
LISTED
NYSE
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
News Preview
GAITHERSBURG, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is proactively working with the World Health Organization (WHO) and the U.S. government to partner and help address the current mpox outbreak across Central Africa, and has pledged to donate 50,000 doses of its ACAM2000®, (Smallpox (Vaccinia)...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
EBS
LISTED
NYSE
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
News Preview
GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
EBS
LISTED
NYSE
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
News Preview
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
EBS
LISTED
NYSE
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
News Preview
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
EBS
LISTED
NYSE
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
News Preview
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
EBS
LISTED
NYSE
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
News Preview
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a tot...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
EBS
LISTED
NYSE
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
News Preview
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general population awareness survey on consumers’ understanding of opioid-related accid...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
EBS
LISTED
NYSE
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
News Preview
GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
EBS
LISTED
NYSE
Emergent BioSolutions Reports First Quarter 2024 Financial Results
News Preview
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
EBS
LISTED
NYSE
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
News Preview
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more than 9 in 10 parents in the survey agr...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
